|

TSLPR-CART Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • B-ALL1
  • Acute Lymphoblastic Leukemia1
  • Cancer1

Bethesda, Maryland1 trial

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Institutes of Health Clinical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.